Sargent, Therese
Tsang, Yuen
Panjabi, Sumeet
Funtanilla, Vienica
Germack, Hayley D.
Gauthier-Loiselle, Marjolaine http://orcid.org/0000-0002-9439-595X
Manceur, Ameur M.
Cloutier, Martin
Lefebvre, Patrick
Funding for this research was provided by:
Janssen Scientific Affairs
Article History
Received: 19 June 2023
Accepted: 18 August 2023
First Online: 20 September 2023
Declarations
:
: Yuen Tsang, Sumeet Panjabi, Vienica Funtanilla, and Hayley D Germack are employees of Janssen Scientific Affairs, LLC and may own stock/stock options. Marjolaine Gauthier-Loiselle, Aameu M Manceur, Martin Cloutier, and Patrick Lefebvre are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, which funded the development and conduct of this study and manuscript. Therese Sargent has received consultancy fees from Janssen Scientific Affairs, LLC. Finally, we note that the study sponsor, Janssen Scientific Affairs, LLC, is a manufacturer of therapies for PH/PAH, including bosentan, epoprostenol, iloprost, macitentan, and selexipag.
: Data were de-identified and comply with the patient requirements of the HIPAA of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) (ExternalRef removed). The present study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.